Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Allucent Expands Use of Medidata Clinical Cloud to Accelerate New Drug Development for Unmet Patient Needs

Medidata, a Dassault Systèmes company, announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.

AiThority Interview : AiThority Interview with Lori Anne, Director of Product Development & Management at Verizon

The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM, and Rave Imaging, in support of critical areas of development, including oncology, rare and orphan indications, and cell and gene therapies. As part of this agreement, Allucent’s team also achieved 100% Rave EDC certification, reinforcing their commitment to quality, and providing their clients with best-in-class technology.

“Our partnership with Medidata allows us to continue to bring our customers the level of patient focus and insights they need and expect,” said Emily Moore, president of Biometrics at Allucent. “Making the Medidata Clinical Cloud platform available to our clients was an important step to enabling us to accelerate clinical trial development for our customers – small and mid-sized biotech companies.”

“Allucent is leveraging the power of the Medidata Clinical Cloud to solidify their position at the forefront of clinical technology,” said Janet Butler, head of Global Sales at Medidata. “Their work with novel therapies requires agile, patient-centric solutions. We are proud to build on our eight-year collaboration to advance the digital transformation of life sciences and deliver clinical innovations to help reach their goals.”

Related Posts
1 of 40,741

Read More InterviewAiThority Interview with Mario Ciabarra, Founder and CEO of Quantum Metric

Allucent, a sponsor of Medidata NEXT London, will make a presentation on data analytics for early phase oncology trials. This includes how working with Medidata has helped them apply strategies and visualization techniques to extract the full value of information for all stakeholders.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

 Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

 [To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.